Duopa Suspension
NDC Package 0074-3012-07

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. NDC HCPCS Crosswalk
    3. Frequently Asked Questions

Package Information

Duopa (carbidopa and levodopa) suspension is a medication used to treat symptoms of Parkinson's disease (such as shakiness, stiffness, difficulty moving). This formulation utilizes a suspension delivery system. Marketed by Abbvie Inc., this product is identified by NDC 0074-3012 and is authorized under FDA application NDA203952.

Identification & Billing

NDC Package Code
0074-3012-07
Package Description
7 CARTRIDGE in 1 CARTON / 100 mL in 1 CARTRIDGE
Product Code
0074-3012
11-Digit Billing Format
00074301207
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk
  • RxCUI: 1599846 - carbidopa 4.63 MG / levodopa 20 MG in 1 mL Enteral Suspension
  • RxCUI: 1599846 - carbidopa 4.63 MG/ML / levodopa 20 MG/ML Oral Suspension
  • RxCUI: 1599846 - carbidopa 4.63 MG/ML (as carbidopa monohydrate 5 MG/ML) / levodopa 20 MG/ML Oral Suspension
  • RxCUI: 1599846 - carbidopa 4.63 MG/ML / L-DOPA 20 MG/ML Oral Suspension
  • RxCUI: 1599852 - Duopa 4.63 MG / 20 MG in 1 mL Enteral Suspension

Clinical Specifications

Proprietary Name
Duopa
Non-Proprietary Name
Carbidopa And Levodopa
Substance Name
Carbidopa Hydrate; Levodopa
Dosage Form
Suspension - A liquid1 dosage form that contains solid particles dispersed in a liquid vehicle.
Administration Route
Enteral - Administration directly into the intestines.
Active Ingredient(s)
Pharmacologic Class
Usage Information
This medication is used to treat symptoms of Parkinson's disease (such as shakiness, stiffness, difficulty moving). Parkinson's disease is thought to be caused by too little of a naturally occurring substance (dopamine) in the brain. Levodopa changes into dopamine in the brain, helping to control movement. Carbidopa prevents the breakdown of levodopa in the bloodstream so more levodopa can enter the brain. Carbidopa can also reduce some of levodopa's side effects such as nausea and vomiting. By giving this medication as a continuous infusion, it can help reduce the amount of "off" time (periods of slow movement or stiffness).

Regulatory & Marketing

Labeler Name
Abbvie Inc.
Product Type
Human Prescription Drug
FDA Application #
NDA203952
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
01-15-2015
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Billing & HCPCS Mapping

To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.

J7340
Source: ASP
Carbidopa levodopa ent 100ml
HCPCS Dosage 5 MG/20 MG 100 ML
Units / Pkg 7

Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0074-3012-07 identifies a specific commercial package of 7 cartridge in 1 carton / 100 ml in 1 cartridge of Duopa, a human prescription drug labeled by Abbvie Inc.. This suspension is formulated for enteral use and contains carbidopa hydrate; levodopa as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Abbvie Inc. on January 15, 2015. The current certification is valid through December 31, 2027.

What are the primary indications for this medication?

This medication is used to treat symptoms of Parkinson's disease (such as shakiness, stiffness, difficulty moving). Parkinson's disease is thought to be caused by too little of a naturally occurring substance (dopamine) in the brain. Levodopa changes into dopamine in the brain, helping to control movement. Carbidopa prevents the breakdown of levodopa in the bloodstream so more levodopa can enter the brain. Carbidopa can also reduce some of levodopa's side effects such as nausea and vomiting. By giving this medication as a continuous infusion, it can help reduce the amount of "off" time (periods of slow movement or stiffness).

How is this Abbvie Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00074301207. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0074-3012-07
11-Digit CMS (5-4-2)
00074-3012-07

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.